市場調查報告書
商品編碼
543578

基因學用實驗室自動化的全球市場:趨勢與預測

Lab Automation in Genomics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球基因學用實驗室自動化市場相關分析,系統概要,及主要推動及市場的阻礙要素,各類型 (各種設備/軟體/計量儀器等) 及各地區的市場趨勢預測,市場競爭環境,主要企業簡介等調查。

第1章 簡介

第2章 本報告的概要

第3章 市場概要

  • 市場區隔
  • 概要
  • 產業的價值鏈分析
  • 產業的向心力:波特的五力分析

第4章 市場動態

  • 簡介
  • 市場的推動要素
  • 市場的阻礙要素

第5章 技術概要

  • 技術現況
  • 在產業的活用狀況

第6章 各種實驗室自動化設備

  • 自動液體處理器
  • 自動盤處理器
  • 機械臂
  • 自動倉庫 (ASRS)

第7章 市場分析與預測

  • 各設備的市場區隔
    • 自動液體處理器
    • 自動盤處理器
    • 機械臂
    • 自動倉庫
  • 軟體市場
    • LIMS (實驗室資訊管理系統)
    • LIS (實驗室資訊系統)
    • CDS (層析法資料系統)
    • ELN (電子實驗筆記本)
    • SDMS (科學資料管理系統)
  • 分析設備市場
    • 生物化學分析設備
    • 免疫系分析設備
    • 血液分析設備
  • 盤式分析儀市場:各種類的明細
    • 吸光強度
    • 螢光光強度
    • 亮度
    • 時間分解螢光光強度
    • 螢光偏光度
    • 光散亂
  • 全球市場:各地區
    • 北美 (美國,加拿大等)
    • 歐洲 (德國,英國,西班牙等)
    • 亞太地區 (日本,中國,韓國等)
    • 其他的國家 (RoW)

第8章 競爭環境

  • 企業合併、收購 (M&A)
  • 合資企業
  • 新產品的銷售
  • 市場收益額前五名公司
  • 過去3年最活躍的企業 (2家)

第9章 企業簡介

第10章 附錄

目錄
Product Code: 47213

The Global Lab Automation in the Genomics market is expected to grow at a CAGR of 7.70% over the forecast period (2021-2026). With the technological advancements and increasing computational capacities, there has been significant improvement in knowledge of genome sequencing in terms of data analytics advances that show unknown correlations, hidden patterns, and other insights, especially when it comes to testing data sets on a large scale.

Key Highlights

  • Moreover, novel advances in medicine are being made rapidly, primarily due to recent developments in genome analysis. DNA sequence analysis provides a clearer understanding of how genetic variation leads to disease and will ultimately lead to new cures. Also, laboratory automation has made room for great flexibility, higher throughputs, and affordable solutions. It offers faster handling, and the process can be expedited without worrying about a lack of reliability and precision. Genotyping and DNA sequencing have been very affordable, due to which the rate of growth is robust.
  • Advances in DNA sequencing technology have made it cost-effective and more accessible than before, which has led to a flurry of genetic testing start-ups. To bring the price down, companies such as Color Genomics and Counsyl have built their sequencing labs and analytics software from scratch, using robots and machine learning to optimize operations.
  • Various genomics applications integrating automation in their processes include nucleic acid isolation, RNAi screening, CRISPR analysis, PCR, and gene expression analysis. Players/Vendors in laboratory automation are designing tools that cater to these application needs. For instance, Tecan Group released their new platform, "Fluent Automation Workstation," in July 2021, which includes various features to simplify day-to-day laboratory automation and boost workflow productivity. During a run, the system reacts dynamically, making adjustments depending on actual times taken to maintain ongoing optimal throughput, all of which can be seen in real-time via an easy-to-understand Gantt chart.
  • Moreover, the companies' other product launches through partnerships, increasing the market share of automation in genomics. For instance, In January 2021, nRichDX Inc. announced the Sample Prep Workflow "Semi-Automated Revolution" to increase sensitivity, yield, and throughput by supplying exponentially more target cfDNA for molecular tests while reducing hands-on technician time.
  • Since the beginning of the COVID-19 epidemic, labs have been converting their spaces and resources into COVID-19 testing facilities, leading to increased adoption of automation equipment. The labs at the University of Washington were the first ones to do this. The Broad Institute followed an announcement of the conversion of their clinical processing lab into a large-scale COVID-19 testing facility.

Key Market Trends

Automated Liquid Handlers to Witness High Growth

  • Cross-contamination is a major problem in the genomics laboratory, which can be avoided by implementing automated systems to manage the reagents and reaction mixtures. It is believed that taking out human intervention helps in achieving more consistency.
  • Many technological advances have been made in the molding of plastics that reduced the volumes of reagents used and enabled the easy handling of smaller liquid volumes. These advancements have worked in favor of the development of micro-and nano-liter plates to fit with the automated liquid handling equipment.
  • Leading companies have set the benchmark for the development of automated liquid handlers. These companies are constantly investing in developing premium products to increase the productivity of the process.
  • According to the Robotic Industries Association, the life science sector has the third-highest growth in industrial robots in terms of automated liquid handlers, automated plate handlers, and robotic arms, among others, to meet up the demand.

North America Occupies the Largest Market Share

  • North America has been a pioneer in clinical research for years. This region is home to major pharmaceutical companies, like Pfizer, Novartis, GlaxoSmithKline, J&J, and Novartis. The part also has the highest concentration of contract research organizations (CROs). Some of the significant CROs are Laboratory Corp. of America Holdings, IQVIA, Syneos Health, and Parexel International Corp. Owing to the presence of all the major players in the industry and stringent FDA regulations; the market is very competitive in the region. To gain an advantage over competitors, the genomics research organizations in the area are increasingly adopting robotics and automation in labs.
  • The genomic industry, especially in the United States, is still growing and is expected to increase over the coming years. The availability of new genome sequencing technologies, well-established healthcare infrastructure, and the increasing geriatric population are significant contributing factors to revenue growth. In the United States, the need to accommodate growth and the drive to boost efficiency are priming blood centers to acquire fully automated walkaway systems to perform types and screens or test specimens for infectious diseases.
  • Many companies are involved in innovation due to their extensive R&D capabilities. For instance, In August 2021, Eli Lilly and Company, in collaboration with Ziath, will open the completely automated Lilly Life Sciences Studio lab in San Diego to speed up the drug discovery process. Individual areas of automation can encompass purification, compound synthesis, biological testing, and analysis in the lab, which is equipped with a Magnamotion track.
  • The spread of COVID-19 has positively impacted the market. When COVID- 19 started in the United States, scientists at the Broad Institute, affiliated with Harvard University and Massachusetts Institute of Technology, realized its genome-reading machines could be repurposed to test patient samples for the coronavirus that causes the disease. Color Genomics, best known for at-home genetic testing for disease risk genes, has also launched a high-throughput, CLIA-certified COVID-19 testing lab.

Competitive Landscape

Lab automation in the genomics market is competitive, owing to many small and big players exporting products to many countries. The key strategies adopted by the major players are technological advancement in development, partnerships, and merger and acquisition. Some of the major players in the market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers, Danaher Corporation, PerkinElmer, and others. Some of the recent developments in the market are :

  • In April 2021, Thermo Fisher Scientific Inc. unveiled their new Collaborative lab automation platform "inSPIRE," which gives users a fully interactive and user-friendly experience. This platform provides a scalable solution for laboratories wishing to reap the benefits of automated processes in terms of throughput, reproducibility, and efficiency.
  • In March 2021, Beckman Coulter Life Sciences introduced "the Biomek NGeniuS workstation," its newest automated liquid handler. The Biomek NGeniuS workstation is built exclusively for NGS library preparation, reducing manual transfers and hands-on time in the usually time-consuming process of library development.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS

  • 4.1 Market Overview
  • 4.2 Value Chain / Supply Chain Analysis
  • 4.3 Industry Attractiveness - Porter's Five Force Analysis
    • 4.3.1 Threat of New Entrants
    • 4.3.2 Bargaining Power of Buyers
    • 4.3.3 Bargaining Power of Suppliers
    • 4.3.4 Threat of Substitute Products
    • 4.3.5 Intensity of Competitive Rivalry
  • 4.4 Assessment of COVID-19 impact on the Industry

5 MARKET DYNAMICS

  • 5.1 Market Drivers
    • 5.1.1 Growing Trend of Digital Transformation for Laboratories with IoT
    • 5.1.2 Effective Management of the Huge Amount of Data Generated
  • 5.2 Market Restraints
    • 5.2.1 Expensive Initial Setup

6 MARKET SEGMENTATION

  • 6.1 By Equipment
    • 6.1.1 Automated Liquid Handlers
    • 6.1.2 Automated Plate Handlers
    • 6.1.3 Robotic Arms
    • 6.1.4 Automated Storage and Retrieval Systems (AS/RS)
    • 6.1.5 Vision Systems
  • 6.2 By Geography
    • 6.2.1 North America
    • 6.2.2 Europe
    • 6.2.3 Asia Pacific
    • 6.2.4 Rest of the World

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Thermo Fisher Scientific Inc.
    • 7.1.2 Danaher Corporation / Beckman Coulter
    • 7.1.3 Hudson Robotics, Inc.
    • 7.1.4 Becton, Dickinson and Company
    • 7.1.5 Synchron Lab Automation
    • 7.1.6 Agilent Technologies Inc.
    • 7.1.7 Siemens Healthineers AG
    • 7.1.8 Tecan Group Ltd
    • 7.1.9 Perkinelmer Inc.
    • 7.1.10 Eli Lilly and Company
    • 7.1.11 F. Hoffmann-La Roche Ltd

8 INVESTMENT ANALYSIS

9 MARKET OPPORTUNITIES AND FUTURE TRENDS